JPS635378B2 - - Google Patents
Info
- Publication number
- JPS635378B2 JPS635378B2 JP53048595A JP4859578A JPS635378B2 JP S635378 B2 JPS635378 B2 JP S635378B2 JP 53048595 A JP53048595 A JP 53048595A JP 4859578 A JP4859578 A JP 4859578A JP S635378 B2 JPS635378 B2 JP S635378B2
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- water
- analgesic
- skin
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 37
- 230000000202 analgesic effect Effects 0.000 claims description 19
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 239000000730 antalgic agent Substances 0.000 claims description 14
- 239000004677 Nylon Substances 0.000 claims description 12
- 229920001778 nylon Polymers 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 230000001760 anti-analgesic effect Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 6
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 24
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 18
- 239000010409 thin film Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000010408 film Substances 0.000 description 14
- 229960001047 methyl salicylate Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 229960002389 glycol salicylate Drugs 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 8
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000005923 long-lasting effect Effects 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229920003169 water-soluble polymer Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- -1 phthalic acid ester Chemical class 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- IZJRISIINLJVBU-UHFFFAOYSA-N beta-Butoxyethyl nicotinate Chemical compound CCCCOCCOC(=O)C1=CC=CN=C1 IZJRISIINLJVBU-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- WIBFFTLQMKKBLZ-SEYXRHQNSA-N n-butyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCC WIBFFTLQMKKBLZ-SEYXRHQNSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- HHAVHBDPWSUKHZ-UHFFFAOYSA-N propan-2-ol;propan-2-one Chemical compound CC(C)O.CC(C)=O HHAVHBDPWSUKHZ-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Description
【発明の詳細な説明】
本発明は、適用時に皮膚表面に薄膜を形成さ
せ、適用初期におけ消炎鎮痛主薬の経皮吸収が大
きく、かつ持続性に優れ、また薄膜剥離時に水等
の溶媒を用いず、容易に除去可能な液状の外用消
炎鎮痛剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention forms a thin film on the skin surface when applied, and the transdermal absorption of the main anti-inflammatory and analgesic drug is large and long-lasting at the initial stage of application. The present invention relates to a liquid external anti-inflammatory analgesic that can be easily removed without being used.
従来、神経痛や筋痛等に対して適用される外用
消炎鎮痛剤としては、サリチル酸メチルやサリチ
ル酸グリコール等の消炎鎮痛主薬にメントール、
カンフル等の添加剤を加え、これらを粘着性基材
に混合して布に延展した貼布剤や軟膏基剤に混合
した軟膏、或いは前記主薬と添加剤を適当な溶剤
に溶解させた液剤、更にこれにエアゾール噴射剤
を加えてエアゾール剤などが知られている。 Traditionally, topical anti-inflammatory analgesics used to treat neuralgia, myalgia, etc. include methyl salicylate, glycol salicylate, and other anti-inflammatory analgesic agents, as well as menthol,
A patch prepared by adding additives such as camphor, mixed with an adhesive base material and spread on cloth, an ointment mixed with an ointment base, or a solution prepared by dissolving the above-mentioned main drug and additives in a suitable solvent. Further, an aerosol agent is known by adding an aerosol propellant to this agent.
しかるに、貼布剤は作用持続性があるものの、
速効性に乏しく、かつ皮膚に長時間貼布すること
により、発汗、呼吸等の皮膚の生理作用を阻害
し、皮膚炎等の刺戟・アレルギートラブルを諾惹
するおそれが多く、更に使用感が悪く、剥離時に
苦痛を伴う場合があり、特に有毛部には適用し難
い等の問題がある。また、軟膏剤は、作用時間が
短かく、かつ適用時にべたつき、汚れ等が生ずる
問題がある。液剤、エアゾール剤は、手軽に塗
布、噴霧が可能で、皮膚トラブルも少なく、使用
感も良好であるが、溶媒が蒸発すると同時に消炎
鎮痛効果も減少し、作用が一過性で持続性に乏し
い等の問題がある。 However, although the patch has a long-lasting effect,
It is not fast-acting, and if it is applied to the skin for a long time, it may inhibit physiological functions of the skin such as sweating and breathing, and may cause irritation and allergy problems such as dermatitis, and it is also uncomfortable to use. However, there are problems such as it may be painful when peeled off, and it is particularly difficult to apply to hairy areas. Further, ointments have problems such as short action time and stickiness, staining, etc. when applied. Liquids and aerosols can be easily applied or sprayed, cause few skin problems, and feel good when used, but as the solvent evaporates, the anti-inflammatory and analgesic effect decreases, and the action is temporary and lacks sustainability. There are other problems.
このように、従来の外用消炎鎮痛剤は、適用面
で種々の問題があると共に、作用の速効性と持続
性とを併せ持つものはなかつた。このため本出願
人は、先に速効性と持続性とを併せ持つ外用消炎
鎮痛剤を薬剤の面から検討することにより提案
し、またその際、鎮痛剤中にポリビニルピロリド
ン・ポリビニルピロリドン・ポリビニルアセテー
ト共重合体等の水溶性高分子を配合することによ
り、適用時、皮膚表面に水溶性高分子の薄膜を形
成し、消炎鎮痛主薬の効果の持続化をより確実に
計ることを提案した（特開昭54−46818号及び
46819号公報）。しかしながら、適用時、皮膚表面
に水溶性高分子樹脂をベースとする被膜を形成す
る方法は、汗や湿気等の影響を受け易いこと、被
膜を剥離除去する際に水洗い等の操作が必要で、
貼布剤に比べて使用性の面で簡便さに欠けるこ
と、更に剤型が水主体により溶媒となるため、被
膜形成に要する乾燥時間が長く、実使用性に欠け
ること等の問題を有しており、また薬剤の面を考
慮せず、前記水溶性高分子被膜を形成させるだけ
の方法によつては、作用の速効性と持続性とを十
分に兼ね備える鎮痛剤は得られないという問題を
有していた。 As described above, conventional external anti-inflammatory analgesics have various problems in terms of application, and none have both fast-acting and long-lasting effects. For this reason, the present applicant first proposed a topical anti-inflammatory analgesic that is both fast-acting and long-lasting by examining it from a drug perspective, and at that time, polyvinylpyrrolidone, polyvinylpyrrolidone, and polyvinyl acetate were included in the analgesic. By blending water-soluble polymers such as polymers, a thin film of water-soluble polymers is formed on the skin surface when applied, and we have proposed that the effects of anti-inflammatory analgesic drugs can be sustained more reliably. No. 54-46818 and
Publication No. 46819). However, the method of forming a film based on water-soluble polymer resin on the skin surface during application is susceptible to the effects of sweat and moisture, and requires operations such as washing with water to peel off and remove the film.
It lacks ease of use compared to patches, and since the dosage form is mainly water, it takes a long time to dry to form a film, making it impractical for practical use. In addition, there is a problem in that an analgesic that has sufficient quick-acting and long-lasting action cannot be obtained by simply forming the water-soluble polymer film without taking drug aspects into consideration. had.
なお従来、このような被膜形成剤としてアクリ
ル酸系樹脂を用い、これに揮発性溶剤に溶解した
だけのものを包帯の代用として使用することが知
られているが、これは手術後などに包帯として用
いるため非常に強い接着力を有し、剥離するとき
に容易にかつ一様のシート丈として剥離すること
はできなかつた。 Conventionally, it has been known to use acrylic acid resin as a film-forming agent, and simply dissolve it in a volatile solvent and use it as a substitute for bandages. Because it is used as a sheet, it has a very strong adhesive force, and when it is peeled off, it cannot be peeled off easily and as a uniform sheet length.
本発明者らは、以上の諸欠点を考慮し、更に鋭
意研究を進せた結果、サリチル酸メチル等の消炎
鎮痛主薬を含む揮発性溶剤に可溶性ナイロン、ポ
リビニルブチラール、及びセルロースアセテート
ブチレートから選ばれるの非水溶性高分子を溶
解、分散させると、適用時に皮膚表面に該非水溶
性高分子の薄膜を速やかに形成し、べたつかず、
かつこの薄膜は皮膚に対する密着性も良好であ
り、しかも皮膚の生理作用を阻害することもな
く、良好に適用し得ると共に、この薄膜を剥離す
る場合、前記主薬を配合していることによる非水
溶性高分子との相乗的作用で一枚の薄皮となつて
簡単に引き剥すことができることを知見した。か
つ、この非水溶性高分子の配合された外用消炎鎮
痛剤は、従来の液剤と同様、薬剤の吸収が速効的
で、適用直後における有効主薬の皮膚への浸透吸
収性が高い上、数時間に亘りその効果を維持する
ことを知見した。そして、このように剤型を工夫
することによつて、使用感が改良され、かつ速効
性と効果の持続性とを併せ持ち、また従来剥離す
る事のなかつた非水溶性高分子が主薬によつて一
枚の膜として良好に剥離することを知見し、本発
明をなすに至つたものである。 In consideration of the above-mentioned drawbacks, the present inventors conducted further intensive research and found that nylon, polyvinyl butyral, and cellulose acetate butyrate, which are soluble in a volatile solvent containing an anti-inflammatory analgesic agent such as methyl salicylate, When the water-insoluble polymer is dissolved and dispersed, a thin film of the water-insoluble polymer is quickly formed on the skin surface when applied, and it is non-sticky and non-sticky.
Moreover, this thin film has good adhesion to the skin and does not inhibit the physiological effects of the skin and can be applied well. It was discovered that due to the synergistic effect with the polymer, it becomes a thin layer that can be easily peeled off. In addition, this topical anti-inflammatory analgesic containing a water-insoluble polymer has rapid drug absorption, similar to conventional liquid preparations, and has high permeability and absorption of the active ingredient into the skin immediately after application, and can last for several hours. It was found that the effect was maintained over a period of time. By devising the dosage form in this way, the feeling of use has been improved, and it has both fast-acting and long-lasting effects, and the main drug is a water-insoluble polymer that does not peel off in the past. It was discovered that the film can be peeled off well as a single film, leading to the present invention.
即ち、本発明は、消炎鎮痛主薬を含む揮発性溶
剤に被膜形成物質として可溶性ナイロン、ポリビ
ニルブチラール及びセルロースアセテートブチレ
ートからなる群より選択される非水溶性高分子物
質の１種又は２種以上を配合してなることを特徴
とする液状の外用消炎鎮痛剤を提供するものであ
る。 That is, the present invention uses one or more water-insoluble polymeric substances selected from the group consisting of nylon, polyvinyl butyral, and cellulose acetate butyrate as a film-forming substance in a volatile solvent containing an anti-inflammatory and analgesic active ingredient. The present invention provides a liquid external anti-inflammatory analgesic characterized by the following:
以下、本発明につき詳しく説明する。 The present invention will be explained in detail below.
本発明において、消炎鎮痛主薬としては、サリ
チル酸メチルやサリチル酸グリコール等、従来よ
り消炎鎮痛主薬として用いられているいずれのも
のをも使用することができる。この場合、サリチ
ル酸メチルやサリチル酸グリコール等は、単独で
使用しても、二種以上を併用しても差支えない
が、外用消炎鎮痛剤を液剤として形成する場合
は、サリチル酸メチルとサリチル酸グリコールと
を重量比で１：９〜９：１、特に３：７〜５：５
の割合で併用することが好ましく、このように両
主薬を併用することにより相乗的効果が発揮され
て、速効性かつ持続性のより優れた外用液剤を製
造することができる。なお、これら主薬の配合量
は、通常処方量の１〜20重量％である。 In the present invention, as the anti-inflammatory analgesic active agent, any of those conventionally used as an anti-inflammatory analgesic active agent, such as methyl salicylate and glycol salicylate, can be used. In this case, methyl salicylate, glycol salicylate, etc. may be used alone or in combination of two or more, but when forming a topical anti-inflammatory analgesic as a liquid, methyl salicylate and glycol salicylate are combined by weight. Ratio of 1:9 to 9:1, especially 3:7 to 5:5
It is preferable to use the two main drugs in combination in a ratio of 1 to 3. By using both the main drugs in combination in this way, a synergistic effect is exhibited, and it is possible to produce a liquid preparation for external use that has better immediate action and longer duration. The amount of these active ingredients is usually 1 to 20% by weight of the prescribed amount.
また、前記主薬に加えて、通常配合される種々
の添加物、例えばｌ−メントール、dl−カンフ
ル、ニコチン酸β−ブトキシエチルなどのニコチ
ン酸エステル類、ビタミンＥ、トウガラシチン
キ、可塑剤（フタル酸エステル、ヒマシ油）等を
配合することができ、更にミリスチン酸イソプロ
ピル、セバチン酸ジエチル、オレイン酸ブチル、
ミリスチン酸オクチルドデシル、ラウリン酸ヘキ
シル等の炭素数が８〜25、特に10〜15の脂肪酸と
炭素数が１〜25、特に２〜５の脂肪族アルコール
とのエステルを１〜20重量％程度配合することが
でき、これら高級脂肪酸エステルの配合により更
に効果の接続性の向上を計ることができる。 In addition to the above-mentioned main drug, various commonly added additives such as l-menthol, dl-camphor, nicotinic acid esters such as β-butoxyethyl nicotinate, vitamin E, chili pepper tincture, and plasticizers (phthalic acid ester, castor oil), etc., as well as isopropyl myristate, diethyl sebatate, butyl oleate,
Contains about 1 to 20% by weight of esters of fatty acids with 8 to 25 carbon atoms, especially 10 to 15 carbon atoms, such as octyldodecyl myristate and hexyl laurate, and aliphatic alcohols with 1 to 25 carbon atoms, especially 2 to 5 carbon atoms. By incorporating these higher fatty acid esters, it is possible to further improve the connectivity of the effect.
本発明において使用される揮発性溶剤は、メタ
ノール、エタノール、イソプロパノールアセト
ン、メチルエチルケトン、水−メタノール、水−
エタノール、水−イソプロパノール、水メチルエ
チルケトン等であり、これら溶剤の１種又は２種
以上が用いられる。 Volatile solvents used in the present invention include methanol, ethanol, isopropanol acetone, methyl ethyl ketone, water-methanol, water-
Ethanol, water-isopropanol, water methyl ethyl ketone, etc., and one or more of these solvents may be used.
そして、本発明においては、前記各成分を適宜
配合してなる外用消炎鎮痛剤に被膜形成物者とし
て非水溶性高分子を溶解、分散させる。非水溶性
高分子としては、可溶性ナイロン（共重合物、変
性ポリアミド等）、ポリビニルブチラール、セル
ロースアセテートブチレートの１種又は２種以上
が使用される。また、これら非水溶性高分子の配
合量は５〜50重量％、特に10〜30重量％とするこ
とが好ましく、この範囲の配合量において上述し
た非水溶性高分子の配合による効果が良好に発揮
される。この場合、前記主薬成分は、非水溶性高
分子に対して５〜400重量％、特に30〜100重量％
配合することが好ましい。主薬がこれより少ない
場合には被膜が容易に剥離することがなく、また
多すぎる場合には十分な被膜強度が得られない。 In the present invention, a water-insoluble polymer is dissolved and dispersed as a film-forming agent in a topical anti-inflammatory analgesic agent prepared by appropriately blending the above-mentioned components. As the water-insoluble polymer, one or more of soluble nylon (copolymer, modified polyamide, etc.), polyvinyl butyral, and cellulose acetate butyrate is used. In addition, the amount of these water-insoluble polymers is preferably 5 to 50% by weight, particularly 10 to 30% by weight, and in this range of amounts, the effect of the above-mentioned water-insoluble polymers is good. Demonstrated. In this case, the main drug component is 5 to 400% by weight, especially 30 to 100% by weight based on the water-insoluble polymer.
It is preferable to mix them. If the amount of the active ingredient is less than this, the coating will not peel off easily, and if it is too much, sufficient coating strength will not be obtained.
このように、本発明に係る外用消炎鎮痛剤は、
消炎鎮痛主薬を含む揮発性溶剤に前記非水溶性高
分子を溶解させるものであり、液剤、もしくはこ
れにフレオン等の通常使用される噴射剤の適宜量
を配合してエアゾール剤の剤型で調製される。 In this way, the external anti-inflammatory analgesic agent according to the present invention is
The above-mentioned water-insoluble polymer is dissolved in a volatile solvent containing an anti-inflammatory and analgesic active ingredient, and it is prepared in the form of a liquid formulation or an aerosol formulation by mixing an appropriate amount of a commonly used propellant such as Freon with this. be done.
而して、この外用消炎鎮痛剤は、適用皮膚面に
塗夫し、或いは噴霧する等により使用するもので
あり、この消炎鎮痛剤が皮膚面に付着されると、
消炎鎮痛剤中の揮発性溶剤が揮散すると共に、そ
の適用皮膚面に前記非水溶性高分子の薄膜が形成
され、消炎鎮痛主薬が直ちに皮膚面より吸収され
て、短時間で適用部位に有効に作用し、効果が速
やかに発揮される上、長時間に亘り持続的に主薬
の吸収維持が行われ、効果が持続する。 Therefore, this external anti-inflammatory analgesic is used by applying it or spraying it on the skin surface, and when this anti-inflammatory analgesic is attached to the skin surface,
As the volatile solvent in the anti-inflammatory analgesic agent evaporates, a thin film of the water-insoluble polymer is formed on the skin surface to which it is applied, and the anti-inflammatory analgesic agent is immediately absorbed from the skin surface and becomes effective at the application site in a short time. Not only does it act quickly, the absorption of the main drug is sustained over a long period of time, resulting in sustained effects.
また、本発明の消炎鎮痛剤は、その適用後、短
時間で乾燥する。従つて前記薄膜の形成が水溶性
高分子を用いた場合に比べて非常に迅速に行われ
るため、簡便に使用でき、かつ形成された前記非
水溶性高分子薄膜はべたつかず、使用感が非常に
優れている。しかも、この薄膜の皮膚に対する密
着性は良好であり、また柔軟さと適度な被膜強度
を有しているため、着用した衣類等の接触や摩擦
で被膜が破損またはよれをおこすこともなく、か
つ適用皮膚面の伸縮に対し確実に追随する。更
に、この薄膜は非水溶性であるため、汗や外界の
湿気、入浴などによつても影響を受けることがな
く、従つて薄膜を脱離させるまで皮膚上に良好に
密着、保持される。また、前記薄膜は適用皮膚面
の伸縮に確実に追随してクラツク状になることが
ない上、完全な透明被膜として形成可能なため、
従来の貼布剤のように適用中に目立つこともない
ので、首筋や手の甲等、人目につく部位にも気薬
に使用できる。 Moreover, the anti-inflammatory and analgesic agent of the present invention dries in a short time after its application. Therefore, since the thin film is formed very quickly compared to when using a water-soluble polymer, it is easy to use, and the formed water-insoluble polymer thin film is not sticky and has a very pleasant feeling when used. Excellent. Moreover, this thin film has good adhesion to the skin, and has flexibility and appropriate film strength, so the film will not be damaged or twisted due to contact or friction with worn clothing, etc., and can be easily applied. Reliably follows the expansion and contraction of the skin surface. Furthermore, since this thin film is water-insoluble, it is not affected by sweat, external humidity, bathing, etc., and therefore adheres well to and remains on the skin until it is removed. In addition, the thin film reliably follows the expansion and contraction of the applied skin surface and does not become crack-like, and can be formed as a completely transparent film.
Unlike conventional patches, it is not noticeable during application, so it can be used on areas that are visible to the public, such as the back of the neck or the back of the hands.
更にまた、本発明に係る外用消炎鎮痛剤は、被
膜形成物質の粒子間の微細な間隙及び被膜自体の
透過性により通気性を保持するため、貼布剤（ゴ
ム膏）のごとく長時間にわたり皮膚の密閉状態に
することがなく、従つて皮膚呼吸の阻害もなく、
皮膚刺激の減少も図ることができる。 Furthermore, the external anti-inflammatory and analgesic agent according to the present invention maintains air permeability due to the fine gaps between the particles of the film-forming substance and the permeability of the film itself, so it remains on the skin for a long time like a patch (gum plaster). There is no need to create an airtight state, so there is no obstruction to skin breathing.
Skin irritation can also be reduced.
なおまた、本発明の鎮痛剤は、上述したように
形成される被膜の皮膚面に対する密着、保持性が
非常に良好であるにもかかわらず、この被膜の剥
離時に当つては、１枚の薄膜として脱離できるの
で、簡単に引き剥すことができる。即ち、上述し
たようにアクリル酸系樹脂などを揮発性溶媒に溶
解しただけのものは、強い接着力を有する反面、
簡単にかつ一枚の薄皮として被膜が剥離するとい
う本発明の目的を達成し得ないものであるが、本
発明は、消炎鎮痛主薬と非水溶性高分子との相乗
的作用により、被膜を容易に一様のシート状とし
て剥離することができるという特徴を有する。か
つ、前記被膜を皮膚より脱離する場合に、痛み等
の苦痛を伴うこともなく、有毛部に対しても好適
に適用できると共に、被膜剥離に際して水洗い等
の操作は不要で、非常に簡便に使用することがで
きる。 Furthermore, although the analgesic of the present invention has a film formed as described above that has very good adhesion and retention properties to the skin surface, when the film is peeled off, only one thin film can be removed. It can be easily peeled off. In other words, as mentioned above, acrylic acid resin or the like simply dissolved in a volatile solvent has strong adhesive strength, but on the other hand,
Although the objective of the present invention of peeling off the coating easily and as a single thin layer cannot be achieved, the present invention does allow the coating to be easily peeled off due to the synergistic action of the anti-inflammatory and analgesic main drug and the water-insoluble polymer. It has the characteristic that it can be peeled off as a uniform sheet. In addition, when the film is removed from the skin, it does not cause any pain or other pain, and it can be suitably applied to hairy areas, and it is very simple and does not require operations such as washing with water when removing the film. It can be used for.
次に実験例を示し、本発明の効果を具体的に説
明する。 Next, experimental examples will be shown to specifically explain the effects of the present invention.
下記組成
サリチル酸グリコール 3.0重量％
サリチル酸メチル 7.0 〃
ｌ−メントール 3.0 〃
dl−カンフル 3.0 〃
可溶性ナイロン（東レ(株)製CM−8000）
15.0 〃
エタノール 69.0 〃
100.0 〃
の試料Ａを調製し、この試料Ａを１群５羽として
家兎の脱毛腰部４×５cmの皮膚表面に均一に点滴
塗布し、その後の皮膚面からの主薬の吸収を血漿
中サリチル酸濃度を指標として測定し、図面に示
す結果を得た。
The following composition Glycol salicylate 3.0% by weight Methyl salicylate 7.0 l-menthol 3.0 dl-camphor 3.0 Soluble nylon (CM-8000 manufactured by Toray Industries, Inc.)
15.0 〃Ethanol 69.0 〃 100.0〃 Sample A was prepared, and this sample A was dripped uniformly onto the skin surface of 4 x 5 cm of the depilated waist area of domestic rabbits in groups of 5, and then the main drug was absorbed from the skin surface. was measured using plasma salicylic acid concentration as an index, and the results shown in the figure were obtained.
また比較のため、市販貼布剤Ｂ、リニメント剤
Ｃを適用した場合の血漿中サリチル酸の経時的濃
度を同様にして測定した。結果を図面に併記す
る。 For comparison, the concentration of salicylic acid in plasma over time was measured in the same manner when commercially available patch B and liniment C were applied. The results are also shown on the drawing.
なお、各試料の塗布量はサリチル酸換算量で20
mgであつた。 The amount of each sample applied is equivalent to 20% salicylic acid.
It was mg.
図面から明らかなように、従来の貼布剤Ｂはあ
る程度の持続的効果を有するものの、適用初期に
おける主薬の経皮吸収量が非常に少なく、速効性
に欠けるものであり、逆にリニメトン剤Ｃは、効
果の持続性が殆んどないものであつた。これに対
し、非水溶性高分子（可溶性ナイロン）を含む試
料Ａは、この非水溶性高分子の薄膜が形成され
て、適用初期における主薬の皮膚への浸透吸収量
が多く、作用の速効性が認められると共に、その
後の血中濃度の維持、持続性が特異的に認めら
れ、本発明による新剤型は、主薬の皮膚への吸収
性、浸透性が適用全期間に亘つて高く、速効性と
作用時間を持続せしめる効果を併せ持つたもので
あることが知見された。 As is clear from the drawings, although the conventional patch B has a certain degree of sustained effect, the amount of transdermal absorption of the main drug at the initial stage of application is very small, and it lacks rapid efficacy.On the contrary, linimeton agent C The effect was almost non-persistent. On the other hand, in sample A containing a water-insoluble polymer (soluble nylon), a thin film of this water-insoluble polymer is formed, and a large amount of the active ingredient permeates and is absorbed into the skin at the initial stage of application, resulting in a fast-acting action. The new dosage form of the present invention has high absorption and permeability of the active ingredient into the skin throughout the application period, and is fast-acting. It was found that it has both the effect of increasing the effectiveness and duration of action.
以上説明したように、本発明は消炎鎮痛主薬を
含む揮発性溶剤に可溶性ナイロン、ポリビニルブ
チラール及びセルロースアセテートブチレートか
らなる群より選択される非水溶性高分子を溶解、
分散させることにより、適用初期における主薬の
経皮吸収が促進され、直ちに患部に作用して速効
的な効果を発揮すると共に、前記非水溶性高分子
の薄膜が形成され。持続的に主薬が皮膚に浸透吸
収されて、適用後数時間以上に亘りその効果が持
続し、強力なる消炎鎮痛作用を発揮して神経痛、
肩こり等の予防、治療を良好に行うことができ
る。また、本発明は水溶性高分子を用いた場合に
比較して速乾性で迅速に薄膜が形成されると共
に、この薄膜は皮膚に対する密着性がよく、また
皮膚の伸縮に良好に追随する上、剥離時に１枚の
薄皮となつて簡単に引き剥すことができ、優れた
剥離性を有する等の特徴を有し、皮膚トラブルも
少なく、使用感、使用に際しての簡便性がいずれ
も良好なものである。 As explained above, the present invention includes dissolving a water-insoluble polymer selected from the group consisting of soluble nylon, polyvinyl butyral, and cellulose acetate butyrate in a volatile solvent containing an anti-inflammatory and analgesic active ingredient.
By dispersing it, transdermal absorption of the main drug is promoted at the initial stage of application, and it immediately acts on the affected area to exert an immediate effect, and a thin film of the water-insoluble polymer is formed. The main drug is continuously absorbed into the skin, and its effect lasts for several hours after application, exerting a powerful anti-inflammatory and analgesic effect that relieves neuralgia,
Stiff shoulders and the like can be effectively prevented and treated. In addition, the present invention dries quickly and quickly forms a thin film compared to when a water-soluble polymer is used, and this thin film has good adhesion to the skin and follows the expansion and contraction of the skin well. When peeled off, it forms a thin layer that can be easily peeled off, has excellent peeling properties, causes few skin problems, and has a good feel and ease of use. be.
以下、実施例を示す。 Examples are shown below.
〔実施例 １〕
常法により下記処方の外用消炎鎮痛液剤を調製
した。[Example 1] A topical anti-inflammatory analgesic solution having the following formulation was prepared by a conventional method.
サリチル酸グリコール 3.0重量％
サリチル酸メチル 7.0 〃
ｌ−メントール 3.0 〃
dl−カンフル 3.0 〃
セルロースアセテートブチレート 20.0 〃
ヒマシ油 7.0 〃
アセトン 37.0 〃
エタノール20.0 〃
100.0 〃
〔実施例 ２〕
常法により下記処方の外用消炎鎮痛液剤を調製
した。 Glycol salicylate 3.0% by weight Methyl salicylate 7.0 l-menthol 3.0 dl-camphor 3.0 cellulose acetate butyrate 20.0 castor oil 7.0 acetone 37.0 ethanol 20.0 100.0 [Example 2] External anti-inflammatory medication prescribed below using the usual method An analgesic solution was prepared.
サリチル酸グリコール 3.0重量％
サリチル酸メチル 7.0 〃
ｌ−メントール 3.0 〃
dl−カンフル 3.0 〃
可溶性ナイロン（東レ(株)製CM−8000）
20.0 〃
エタノール 64.0 〃
100.0 〃
〔実施例 ３〕
常法により下記処方の外用消炎鎮痛液剤を調製
した。 Glycol salicylate 3.0% by weight Methyl salicylate 7.0 l-menthol 3.0 dl-camphor 3.0 Soluble nylon (CM-8000 manufactured by Toray Industries, Inc.)
20.0 〃Ethanol 64.0 〃 100.0 〃 [Example 3] A topical anti-inflammatory analgesic solution having the following formulation was prepared by a conventional method.
サリチル酸メチル 10.0重量％
ｌ−メントール 3.0 〃
dl−カンフル 3.0 〃
可溶性ナイロン（CM−8000） 13.0 〃
エタノール 71.0 〃
100.0 〃
〔実施例 ４〕
常法により下記処方の外用消炎鎮痛液剤を調製
した。 Methyl salicylate 10.0% by weight l-menthol 3.0 dl-camphor 3.0 soluble nylon (CM-8000) 13.0 ethanol 71.0 100.0 [Example 4] A topical anti-inflammatory analgesic solution with the following formulation was prepared by a conventional method.
サリチル酸グリコール 3.0重量％
サリチル酸メチル 7.0 〃
ｌ−メントール 3.0 〃
dl−カンフル 3.0 〃
ポリビニルブチラール 20.0 〃
ヒマシ油 2.0 〃
エタノール 62.0 〃
100.0 〃
〔実施例 ５〕
常法により下記処方の外用消炎鎮痛エアゾール
剤を調製した。 Glycol salicylate 3.0% by weight Methyl salicylate 7.0 l-menthol 3.0 dl-camphor 3.0 polyvinyl butyral 20.0 castor oil 2.0 ethanol 62.0 100.0 [Example 5] External anti-inflammatory analgesic with the following prescription by the usual method Prepare aerosol did.
サリチル酸メチル 2.0重量％
ｌ−メントール 1.0 〃
チモール 0.5 〃
dl−カンフル 1.0 〃
ジクロルジフルオロメタン 30.0 〃
トリクロロフルオロメタン 45.5 〃
可溶性ナイロン（東レ(株)製CM−9000）
5.0 〃
エタノール 15.0 〃
100.0 〃
実施例１〜５で得られた消炎鎮痛剤は、いずれ
も作用の速効性と持続性とを併せもち、また適用
後速やかに乾燥して１分程度で薄膜が形成される
と共に、べとつきのない良好な使用感を有し、か
つ皮膚呼吸等の阻害のない、皮膚トラブルを生ず
るおそれれの少ないものであり、また前記薄膜は
１枚の薄皮状に簡単に引き剥し得るものであつ
た。また、サリチル酸メチル、サリチル酸グリコ
ールと可溶性ナイロンとを組合せたものは、可溶
性ナイロンのゲル化が生じることのないものであ
り、いずれも保存安定性に優れたものであつた。 Methyl salicylate 2.0% by weight L-menthol 1.0 Thymol 0.5 dl-camphor 1.0 Dichlorodifluoromethane 30.0 Trichlorofluoromethane 45.5 Soluble nylon (CM-9000 manufactured by Toray Industries, Inc.)
5.0 〃Ethanol 15.0 〃 100.0 〃 The anti-inflammatory analgesics obtained in Examples 1 to 5 all have both fast-acting and long-lasting action, and quickly dry to form a thin film in about 1 minute after application. In addition, it has a good feel without stickiness, does not inhibit skin breathing, and is less likely to cause skin problems, and the thin film can be easily peeled off into a single thin layer. It was something to gain. Furthermore, the combinations of methyl salicylate, glycol salicylate, and soluble nylon did not cause gelation of the soluble nylon, and both had excellent storage stability.
図面は本発明の一実施例と市販外用消炎鎮痛剤
をそれぞれ適用した場合における血漿中サリチル
酸濃度の経時的変化を示すグラフである。
The figure is a graph showing changes in plasma salicylic acid concentration over time when one embodiment of the present invention and a commercially available topical anti-inflammatory analgesic were applied.
Claims (1)
質として可溶性ナイロン、ポリビニルブチラール
及びセルロースアセテートブチレートからなる群
より選択される非水溶性高分子物質の１種又は２
種以上を配合してなることを特徴とする液状の外
用消炎鎮痛剤。 ２ 消炎鎮痛主薬を非水溶性高分子物質に対し５
〜400重量％配合した特許請求の範囲第１項記載
の外用消炎鎮痛剤。 ３ 消炎鎮痛主薬を非水溶性高分子物質に対し30
〜100重量％配合した特許請求の範囲第２項記載
の外用消炎鎮痛剤。[Scope of Claims] 1. One or two water-insoluble polymeric substances selected from the group consisting of nylon, polyvinyl butyral, and cellulose acetate butyrate, which are soluble in volatile solvents containing anti-inflammatory and analgesic agents as film-forming substances.
A liquid external anti-inflammatory analgesic characterized by containing at least one of the following: 2 Anti-inflammatory and analgesic main drug for water-insoluble polymer substances 5
The external anti-inflammatory analgesic agent according to claim 1, containing ~400% by weight. 3. 30% anti-inflammatory analgesic drug for water-insoluble polymer substances
The external anti-inflammatory and analgesic agent according to claim 2, containing ~100% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4859578A JPS54140713A (en) | 1978-04-24 | 1978-04-24 | Surgical antiiinflammatory and anodyne agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4859578A JPS54140713A (en) | 1978-04-24 | 1978-04-24 | Surgical antiiinflammatory and anodyne agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS54140713A JPS54140713A (en) | 1979-11-01 |
| JPS635378B2 true JPS635378B2 (en) | 1988-02-03 |
Family
ID=12807749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4859578A Granted JPS54140713A (en) | 1978-04-24 | 1978-04-24 | Surgical antiiinflammatory and anodyne agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS54140713A (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6016922A (en) * | 1983-07-08 | 1985-01-28 | Nitto Electric Ind Co Ltd | Administration of drug for transcutaneous absorption |
| JPS6064921A (en) * | 1983-09-16 | 1985-04-13 | Tanpei Seiyaku Kk | Skin-coating agent |
| JPS60228412A (en) * | 1984-04-27 | 1985-11-13 | Terumo Corp | Antimycotic agent for external application |
| JPS6183117A (en) * | 1984-09-28 | 1986-04-26 | Sumitomo Chem Co Ltd | Aerosol agent |
| JPH0794378B2 (en) * | 1989-08-18 | 1995-10-11 | 久光製薬株式会社 | Aerosol |
| WO2003105841A1 (en) * | 2002-06-18 | 2003-12-24 | ポーラ化成工業株式会社 | Antifungal medicinal compositions |
| JP2004359585A (en) * | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | Coating film-forming type external preparation containing adrenocorticosteroid medicine |
| JP2006131544A (en) * | 2004-11-05 | 2006-05-25 | Medorekkusu:Kk | External preparation for treating skin disorder |
| JP2018000390A (en) * | 2016-06-29 | 2018-01-11 | 有限会社日本健康科学研究センター | Acidic artificial keratin-forming preparation |
| TWI805687B (en) | 2018-02-08 | 2023-06-21 | 日商花王股份有限公司 | Composition for coating film formation |
-
1978
- 1978-04-24 JP JP4859578A patent/JPS54140713A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS54140713A (en) | 1979-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8741332B2 (en) | Compositions and methods for dermally treating neuropathic pain | |
| US8741333B2 (en) | Compositions and methods for treating dermatitis or psoriasis | |
| US20070189980A1 (en) | Compositions and methods for treating alopecia | |
| US20080019927A1 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
| US20070196293A1 (en) | Compositions and methods for treating photo damaged skin | |
| US5082663A (en) | External adhesive preparation containing steroids | |
| JP2735392B2 (en) | How to treat psoriasis | |
| CN101677969B (en) | Matrix-type transdermal drug delivery system and preparation method thereof | |
| AU614179B2 (en) | Compositions and in situ methods for forming films on body tissue | |
| JP2009519940A (en) | Compositions and methods for treating dermatological conditions | |
| JP2009524586A (en) | Compositions and methods for skin treatment of pain | |
| JP2014001218A (en) | Adhesive peel formation formulation for dermal delivery of drug and method using the same | |
| JP2003514835A (en) | Methods and compositions for treating scarring | |
| JPH10152433A (en) | Film-forming antifungal agent composition | |
| JPS635378B2 (en) | ||
| CA2747845A1 (en) | Compositions and methods for dermally treating pain | |
| JP2797401B2 (en) | Antifungal composition for nails | |
| JPH10330247A (en) | Plaster for nail | |
| JP3525391B2 (en) | Surface stabilized preparations for skin application | |
| JPS60163811A (en) | External application pharmaceutical containing propranolol | |
| JPH01230514A (en) | Aerosol type patch external use | |
| KR19980076273A (en) | Film-forming gel composition for transdermal absorption | |
| JPH11180887A (en) | Anti-inflammatory analgesic patch | |
| JPH092943A (en) | Film-forming type solution for external use | |
| JPS5878663A (en) | Rapid drying film forming base agent |